Spatiotemporal analysis of mycolactone distribution in vivo reveals partial diffusion in the central nervous system.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
12 2020
Historique:
received: 05 06 2020
accepted: 13 10 2020
entrez: 2 12 2020
pubmed: 3 12 2020
medline: 23 2 2021
Statut: epublish

Résumé

Mycobacterium ulcerans, the causative agent of Buruli ulcer (BU) disease, is unique amongst human pathogens in its capacity to produce a lipid toxin called mycolactone. While previous studies have demonstrated that bacterially-released mycolactone diffuses beyond infection foci, the spatiotemporal distribution of mycolactone remained largely unknown. Here, we used the zebrafish model to provide the first global kinetic analysis of mycolactone's diffusion in vivo, and multicellular co-culture systems to address the critical question of the toxin's access to the brain. Zebrafish larvae were injected with a fluorescent-derivative of mycolactone to visualize the in vivo diffusion of the toxin from the peripheral circulation. A rapid, body-wide distribution of mycolactone was observed, with selective accumulation in tissues near the injection site and brain, together with an important excretion through the gastro-intestinal tract. Our conclusion that mycolactone reached the central nervous system was reinforced by an in cellulo model of human blood brain barrier and a mouse model of M. ulcerans-infection. Here we show that mycolactone has a broad but heterogenous profile of distribution in vivo. Our investigations in vitro and in vivo support the view that a fraction of bacterially-produced mycolactone gains access to the central nervous system. The relative persistence of mycolactone in the bloodstream suggests that assays of circulating mycolactone are relevant for BU disease monitoring and treatment optimization.

Identifiants

pubmed: 33264290
doi: 10.1371/journal.pntd.0008878
pii: PNTD-D-20-00990
pmc: PMC7710047
doi:

Substances chimiques

Bacterial Toxins 0
Macrolides 0
mycolactone 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0008878

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Pharmacol Res. 2017 Nov;125(Pt B):246-257
pubmed: 28867638
Microbes Infect. 2012 Aug;14(9):719-29
pubmed: 22465732
Medicines (Basel). 2019 May 30;6(2):
pubmed: 31151179
PLoS Negl Trop Dis. 2017 Nov 17;11(11):e0006058
pubmed: 29149212
Biol Cell. 2018 Nov;110(11):237-248
pubmed: 30055020
PLoS Pathog. 2018 Jul 17;14(7):e1007157
pubmed: 30016370
Blood. 2008 Jan 1;111(1):132-41
pubmed: 17875807
J Clin Invest. 2013 Apr;123(4):1501-12
pubmed: 23549080
Fluids Barriers CNS. 2013 Mar 26;10(1):16
pubmed: 23531482
Toxins (Basel). 2019 Apr 04;11(4):
pubmed: 30987300
Trends Microbiol. 2020 Jan;28(1):10-18
pubmed: 31604611
ACS Nano. 2018 Mar 27;12(3):2138-2150
pubmed: 29320626
Biologicals. 2018 May;53:19-29
pubmed: 29580693
Front Immunol. 2018 May 24;9:1084
pubmed: 29881380
PLoS Negl Trop Dis. 2011 Jul;5(7):e1237
pubmed: 21811642
Dev Biol. 2020 Jan 15;457(2):181-190
pubmed: 30862465
Science. 1999 Feb 5;283(5403):854-7
pubmed: 9933171
Am J Trop Med Hyg. 2019 Dec;101(6):1312-1321
pubmed: 31595865
Chem Commun (Camb). 2010 Mar 7;46(9):1410-2
pubmed: 20162131
PLoS Negl Trop Dis. 2008;2(10):e325
pubmed: 18941518
J Med Chem. 2014 Sep 11;57(17):7382-95
pubmed: 25158122
J Exp Med. 2016 Dec 12;213(13):2885-2896
pubmed: 27821549
Nat Rev Drug Discov. 2005 Jan;4(1):35-44
pubmed: 15688071
Nat Rev Microbiol. 2009 Jan;7(1):50-60
pubmed: 19079352
J Cell Sci. 2011 Sep 15;124(Pt 18):3053-9
pubmed: 21868367
Cell Death Dis. 2018 Mar 14;9(3):397
pubmed: 29540678
Infect Immun. 1998 Feb;66(2):587-93
pubmed: 9453613
Chemistry. 2011 Dec 16;17(51):14413-9
pubmed: 22127975
J Cell Sci. 2016 Apr 1;129(7):1404-15
pubmed: 26869228
J Cell Physiol. 1987 Jul;132(1):111-7
pubmed: 3597548
Genes Dev. 2008 Mar 15;22(6):734-9
pubmed: 18347092
J Med Chem. 2009 Nov 12;52(21):6752-6
pubmed: 19827778
Nat Commun. 2015 Sep 28;6:8375
pubmed: 26411530
Nat Prod Rep. 2013 Dec;30(12):1527-67
pubmed: 24178858
PLoS Negl Trop Dis. 2010 Jul 27;4(7):e663
pubmed: 20668542
J Vis Exp. 2019 Apr 9;(146):
pubmed: 31033945
Sci Transl Med. 2015 May 27;7(289):289ra85
pubmed: 26019221
PLoS One. 2010 May 24;5(5):e10777
pubmed: 20520722
J Immunol. 2009 Feb 15;182(4):2194-202
pubmed: 19201873
Biochem Soc Trans. 2014 Feb;42(1):177-83
pubmed: 24450648
J Infect Dis. 2009 Dec 1;200(11):1675-84
pubmed: 19863437
Genes Dev. 2018 Apr 1;32(7-8):466-478
pubmed: 29692355
Nature. 2013 Apr 25;496(7446):498-503
pubmed: 23594743
PLoS Pathog. 2013;9(9):e1003588
pubmed: 24039575
Nat Methods. 2012 Jun 28;9(7):690-6
pubmed: 22743774
Front Cell Neurosci. 2013 Jan 30;7:3
pubmed: 23386810

Auteurs

Emma Colucci-Guyon (E)

Macrophages and Development of Immunity, Institut Pasteur, CNRS UMR 3738, Paris, France.

Aline Rifflet (A)

Institut Pasteur, Unité Biologie et génétique de la paroi bactérienne, Paris 75724, France; CNRS, UMR 2001 "Microbiologie intégrative et moléculaire", Paris 75015, France; INSERM, groupe Avenir, Paris, France.

Sarah Saint-Auret (S)

Université de Haute-Alsace, Université de Strasbourg, CNRS, LIMA, UMR 7042, Mulhouse, France.

Anaëlle da Costa (A)

Viral Neuroimmunology, Institut Pasteur, Paris, France.

Laurent Boucontet (L)

Macrophages and Development of Immunity, Institut Pasteur, CNRS UMR 3738, Paris, France.

Thomas Laval (T)

Immunobiology of Infection Unit, Institut Pasteur, INSERM U1221, Paris, France.
Université Paris Diderot, Sorbonne Paris Cité, Paris, France.

Christophe Prehaud (C)

Viral Neuroimmunology, Institut Pasteur, Paris, France.

Nicolas Blanchard (N)

Université de Haute-Alsace, Université de Strasbourg, CNRS, LIMA, UMR 7042, Mulhouse, France.

Jean-Pierre Levraud (JP)

Macrophages and Development of Immunity, Institut Pasteur, CNRS UMR 3738, Paris, France.

Ivo G Boneca (IG)

Institut Pasteur, Unité Biologie et génétique de la paroi bactérienne, Paris 75724, France; CNRS, UMR 2001 "Microbiologie intégrative et moléculaire", Paris 75015, France; INSERM, groupe Avenir, Paris, France.

Caroline Demangel (C)

Immunobiology of Infection Unit, Institut Pasteur, INSERM U1221, Paris, France.

Laure Guenin-Macé (L)

Immunobiology of Infection Unit, Institut Pasteur, INSERM U1221, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH